145 related articles for article (PubMed ID: 38537440)
21. Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXR
You W; Li L; Sun D; Liu X; Xia Z; Xue S; Chen B; Qin H; Ai J; Jiang H
Cancer Immunol Res; 2019 Jun; 7(6):990-1000. PubMed ID: 30975694
[TBL] [Abstract][Full Text] [Related]
22. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
23. Z-guggulsterone induces PD-L1 upregulation partly mediated by FXR, Akt and Erk1/2 signaling pathways in non-small cell lung cancer.
Tian H; Gui Y; Wei Y; Shang B; Sun J; Ma S; You W; Jiang S
Int Immunopharmacol; 2021 Apr; 93():107395. PubMed ID: 33529916
[TBL] [Abstract][Full Text] [Related]
24. Targeting the Ang2/Tie2 Axis with Tanshinone IIA Elicits Vascular Normalization in Ischemic Injury and Colon Cancer.
Zou W; Qian C; Zhang S; Wan X; Wei Z; Li X; Wu Y; Chen W; Wang A; Zhao Y; Lu Y
Oxid Med Cell Longev; 2021; 2021():7037786. PubMed ID: 34804370
[TBL] [Abstract][Full Text] [Related]
25. Tanshinone IIA combined with cisplatin synergistically inhibits non-small-cell lung cancer in vitro and in vivo via down-regulating the phosphatidylinositol 3-kinase/Akt signalling pathway.
Liao XZ; Gao Y; Huang S; Chen ZZ; Sun LL; Liu JH; Chen HR; Yu L; Zhang JX; Lin LZ
Phytother Res; 2019 Sep; 33(9):2298-2309. PubMed ID: 31268205
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer.
Zhang H; Liu P; Zhang Y; Han L; Hu Z; Cai Z; Cai J
FEBS Open Bio; 2021 Mar; 11(3):911-920. PubMed ID: 33455075
[TBL] [Abstract][Full Text] [Related]
27. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
28. Tumor-associated macrophages (TAMs)-derived osteopontin (OPN) upregulates PD-L1 expression and predicts poor prognosis in non-small cell lung cancer (NSCLC).
Li Y; Liu H; Zhao Y; Yue D; Chen C; Li C; Zhang Z; Wang C
Thorac Cancer; 2021 Oct; 12(20):2698-2709. PubMed ID: 34423566
[TBL] [Abstract][Full Text] [Related]
29. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC).
Hong W; Xue M; Jiang J; Zhang Y; Gao X
J Exp Clin Cancer Res; 2020 Aug; 39(1):149. PubMed ID: 32746878
[TBL] [Abstract][Full Text] [Related]
30. KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway.
Du W; Zhu J; Zeng Y; Liu T; Zhang Y; Cai T; Fu Y; Zhang W; Zhang R; Liu Z; Huang JA
Cell Death Differ; 2021 Apr; 28(4):1284-1300. PubMed ID: 33139930
[TBL] [Abstract][Full Text] [Related]
31. Monitoring the Response of PD-L1 Expression to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonsmall-Cell Lung Cancer Xenografts by Immuno-PET Imaging.
Li D; Zou S; Cheng S; Song S; Wang P; Zhu X
Mol Pharm; 2019 Aug; 16(8):3469-3476. PubMed ID: 31283253
[TBL] [Abstract][Full Text] [Related]
32. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.
Pang L; Han S; Jiao Y; Jiang S; He X; Li P
Int J Oncol; 2017 Jul; 51(1):25-38. PubMed ID: 28534943
[TBL] [Abstract][Full Text] [Related]
33. Tanshinone IIA reverses gefitinib resistance in EGFR-mutant lung cancer via inhibition of SREBP1-mediated lipogenesis.
Zhang L; Xu C; Huang J; Jiang S; Qin Z; Cao L; Tan G; Zhao Z; Huang M; Jin J
Phytother Res; 2024 Mar; 38(3):1574-1588. PubMed ID: 38282115
[TBL] [Abstract][Full Text] [Related]
34. Evodiamine suppresses non-small cell lung cancer by elevating CD8
Jiang ZB; Huang JM; Xie YJ; Zhang YZ; Chang C; Lai HL; Wang W; Yao XJ; Fan XX; Wu QB; Xie C; Wang MF; Leung EL
J Exp Clin Cancer Res; 2020 Nov; 39(1):249. PubMed ID: 33208183
[TBL] [Abstract][Full Text] [Related]
35. Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.
Luo F; Luo M; Rong QX; Zhang H; Chen Z; Wang F; Zhao HY; Fu LW
J Immunother Cancer; 2019 Sep; 7(1):245. PubMed ID: 31511071
[TBL] [Abstract][Full Text] [Related]
36. c-Jun N-terminal Kinase-Dependent Endoplasmic Reticulum Stress Pathway is Critically Involved in Arjunic Acid Induced Apoptosis in Non-Small Cell Lung Cancer Cells.
Joo H; Lee HJ; Shin EA; Kim H; Seo KH; Baek NI; Kim B; Kim SH
Phytother Res; 2016 Apr; 30(4):596-603. PubMed ID: 26787261
[TBL] [Abstract][Full Text] [Related]
37. Tanshinone IIA induces apoptosis in human lung cancer A549 cells through the induction of reactive oxygen species and decreasing the mitochondrial membrane potential.
Chiu TL; Su CC
Int J Mol Med; 2010 Feb; 25(2):231-6. PubMed ID: 20043132
[TBL] [Abstract][Full Text] [Related]
38. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
[TBL] [Abstract][Full Text] [Related]
39. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
[TBL] [Abstract][Full Text] [Related]
40. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
